NeuroSense Therapeutics Ltd【NRSN】株式ニュース

個人投資家向けのプロ仕様のツール。

プレミアム

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass...

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC PR Newswire CAMBRIDGE, Mass...

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival...

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price PR...

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND PR Newswire CAMBRIDGE...

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission PR Newswire CAMBRIDGE...

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients PR Newswire CAMBRIDGE, Mass., Oct...

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides...

Nobody claims a multibillion dollar partnership. Read the headlines. They are in discussions with several multi- billion dollar companies for partnerships. Also, they could have done a large public offering to keep the lights on as they are nasdaq listed. Instead the ceo chose to do a private placement and buy 5 million worth. The partnerships are for funding the continued trials and I know alot about how things work with pharma as I've been trading bios 20 years. The data is impressive and worth Billions and as the market catches on expect significant rises in the share price

👍️0

runncoach 2日前

How much do you think a P3 cost? That's why so little leverage. Why didn't they already get a partnership they've talked about for 4 months? It's not easy when you don't have cash. It's not going to be a multi billion partnership that I've seen some posting about. Ceo kept them listed and gave a couple months breathing room. Congrats to him

👍️0

johnhancoque 2日前

Right. You believe he did it to keep the lights on when he could have done a public offering for alot more. Instead, he spent 5 million of his own money suggesting he has faith in a very large partnership. Your way of thinking is twisted. No need reply again

👍️0

runncoach 2日前

I'm suggesting he bought to keep the company's listing and float the company til they find funding since they can't fund a P3 trial. It's not a strong position to negotiate from. I don't think I'm saying anything controversial or that isn't common sense at this point. I expect them to find something and then there will be a very long wait

👍️0

johnhancoque 2日前

You're suggesting the ceo bought 5 million worth of stock this month well above market value because he may not succeed in finding a partner? That sounds ridiculous buddy. It's more likely he is very confident in finding a partnership or is in the final stages so he bought 5 million worth. Your understanding of how insiders buys shares is out to bloody lunch. Hardly anyone would spend 5 million on a single stock without a near sure bet let alone a ceo of a publicly traded company

👍️0

johnhancoque 2日前

A ceo who had no faith in a partnership sure as he'll wouldn't pony up 5 million bucks if there was nothing in the works. Don't miss the forest for the trees. He bought 5 million worth because a partnership is in the works.
Smh

👍️0

runncoach 2日前

Been here long before you. Ceo ponied up money to meet Nasdaq requirements. Stock got shorted down so the "raise" price would look better.

Doesn't take a genius to realize not having the cash to even make it to the start of launching a P3 next summer isn't negotiating from a position of strength. If they don't get a partnership there would have to be a very unfavorable money raise to launch the trial. Between a rock and a hard place as far as negotiating.

Let's hope they get a partnership on favorable terms and a nice spike before the stock pulls back with the markets realizing another 12+ months til Canadian news and much longer than that for US.

👍️0

johnhancoque 2日前

So now and ceo who buys 5 million worth of stock isn't a good sign, it's a bad sign of a pump? Where do you guys come from, really?
Even with good news you shorts twist things unrecognizable. Truly unbelievable
The ceo bought 5 million worth 30% above the then market price. They don't need cash they need a partnership which they will have no problem finding and are in discussions right now with several Big Pharmas. Drugs like this don't go unnoticed long with Big pharma sniffing around. Just sell and get lost because your comments are useless to the investing community

👍️0

runncoach 2日前

Was wondering about the pump.

Folks will soon learn you don't get billion dollar partnerships when the CEO is having to buy stock to keep the lights on I'm afraid. Give me 3 bucks and I'll sit this one out for a while.

👍️0

johnhancoque 2日前

$7.50 Cantor price target 🥱👀

👍️0

runncoach 3日前

Not immediately it won't, no. Not in a price sustainable way that is. I own shares but will sell any significant spikes and buy back lower to hold long term

👍️0

johnhancoque 3日前

You don't understand. A partnership with BP takes NRSN to the next level no looking back. Once a partnership is announced with a large upfront payment, there will be no looking back for this company, ever. It will be bought by BIg Pharma long before p3 results. Easy to manufacture and worldwide protection until 2044

👍️0

runncoach 3日前

The problem is there is a large number of warrant shares available that will keep a lid on the share price after any spikes. Company has low funds considering it has yet to begin their P3. Sales are 2-3 years away at the least. Details of any partnership will be very important concerning future potential money raises. Sell significant spikes is my advice because folks sitting on warrants likely will. JMHO

👍️0

johnhancoque 3日前

$9.25 price target. Partnership news looks imminent. Only 25 million market cap has 400% to run at a minimum here

👍️0

johnhancoque 4日前

CEO bought 5 million worth and no matter how you spin that it will always be a boon for the company and shareholders. Regardless of what you say, any ceo who puts up 5 million bucks and above market for that matter says everything about where the sp is headed nearterm and speaks volumes about the confidence he has in his company and the data. Simple as that!

👍️0

McMagyar 4日前

Except
The value would have already rocketed well past $1.25.. with so few shares out.. and after the news hit, the company could have raised the same amount of money by issuing fewer shares, less dilution, shares more valuable.. now only one shareholder benefits from knowing the good news.. sure looks like a shareholder lawsuit to me.. greed sucks.. maybe the other shareholders will let it go.. maybe they won't..
You can't control what happens, but you can control with whom you do bizness..
Thx Barrister.. wise words

👍️0

johnhancoque 5日前

All that matters is he bought 5 million shares @ $1.25 and the share price is about to rocket hard. Analysts price targets north of $12.00

👍️0

McMagyar 5日前

This smells a lot like stealing to me..
All the other shareholders got diluted.. while the sole stock buyer of issuance becomes kazillionairre.. sounds like an attorney would want to know what the shareholder who bought all this stock knew.. and why the offering wasn't made to other shareholders?

👍️0

johnhancoque 5日前

Insider trading doesn't mean insiders can't buy shares or participate in offerings. There are however windows they have to abide by and if a significant partnership is announced in January they are well within their time to buy shares

That would look quite a bit like inside trading if they did that the next couple months. Trust me I hope so but doesn't look good to me.

👍️0

johnhancoque 6日前

$25.00 with partnership and large upfront payment

👍️0

johnhancoque 6日前

Um....he sold himself the last offering because there is a multi Billion dollar partnership about to be signed

👍 1

McMagyar 3週前

It was a money raise to one guy.. total bullshit. Thief

👍️0

runncoach 3週前

The issue to me is the stock was sold down the last 2 or 3 weeks on "no news" and then we get a low price money raise. Doesn't look good

👍️0

McMagyar 3週前

Co issues 12,000,000 share rights to one guy right before good news hits? What a legal Scally wag.. what's to stop him from issuing himself another 10,000,000? Know them but their greed.
What a crock

👍️0

runncoach 3週前

Today's PR would certainly lead one to believe no partnership type of completion until next year at the earliest IMO

👍️0

runncoach 3週前

Just under 21 million

From this evening's 6K. No idea if it's BS or not.
NeuroSense Therapeutics Ltd. (the Company) hereby reports that it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership for the development and commercialization of its lead drug candidate, PrimeC, for the treatment of Amyotrophic Lateral Sclerosis (ALS).

These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments and royalty payments as part of an agreement. NeuroSense anticipates receiving terms from these discussions in Q4 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what would be the final terms, if any, or that a definitive agreement will be reached.

👍️0

runncoach 4月前

Money raise with .75 warrants attached fyi. Now we know why the price has remained so low IMO

👍️0

vein 5月前

Thanks much for the insight !

👍️0

runncoach 5月前

Who knows? Unless you are trading the stock, real results are a long ways off IMO and that can lead to opportunity cost. If it's a small percentage of a speculative portfolio the current price probably isn't bad. Just depends on your patience level

👍️0

vein 5月前

Why the sell off ?? Thanks in advance!

👍️0

vein 5月前

Seems like a decent entry ?

👍️0

runncoach 5月前

The data is good but they'll have to raise money for a P3 so these guys are still a ways off IMO. They've mentioned a potential Biogen partnership last year yet here we stand. I do believe the drug is safe and has a real chance. Timing is everything.

👍️0

vein 5月前

Time to buy now ??? Newbie here! Any thoughts ??

Great data out. On to P3. Only thing that will likely sustain share price after this rally is partnership IMO.

Certainly showing a positive trend on the scientific front.
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93791685/neurosense-announces-new-positive-data-analysis-fr

👍️0

runncoach 8月前

Financing broke the stock for now. Either Biogen news or dead money IMO

👍️0

runncoach 8月前

Looks like there will be a data presentation on the sixteenth at a conference. Back in for a gamble at 1.70.

👍️0

runncoach 8月前

And there's the money raise at 1.50

👍️0

runncoach 9月前

Sold at 2.12. Only update today on the additional biomarker data was talking about peer reviews and conferences. I expected data at least a month ago. I'm concerned they'll raise money before we get any significant data updates. I could be making a mistake but taking profits from .79 so can't be too upset if I do. I'll buy back if it goes lower most likely. GLTA

👍️0

glenn1919 9月前

NRSN..........................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783

I like Coya a lot as well. I was hoping to see how the Biogen data plays out here and then moving funds there. Hopefully I'll get that chance. I'm not sure COYA's next coming data will be ideal based on the dosage and other trial parameters but could give a great indication to set up a pivotal P3. Lot of bigger money over there. I've got my eyes on them for sure. JMHO

👍️0

FooBarAndGrill 9月前

Suggest a look at $COYA for ALS.

👍️0

runncoach 10月前

Disappointed for the ALS community. Hoping NRSN can provide some hope.
https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-topline-results-120000695.html?guccounter=1&guce_referrer=YW5kcm9pZC1hcHA6Ly9jb20uZ29vZ2xlLmFuZHJvaWQuZ29vZ2xlcXVpY2tzZWFyY2hib3gv&guce_referrer_sig=AQAAAAM8h3Ee_7hkwe__ixrWmntWVPdxe8WZ1ZpxVn7ZSc5Y_cvU8dUOeH8gNnkII0GDb_rsadt-ieRtojdTcEbDoBluMPdmwoVEaO7k8HMPi6OgMQhLipitwShkj668qEiwBreTeVNkxishXrsTPgOOOMTmvMybqLk3QVA9AiTxt2Bt

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター